Basille D, Andrejak C
Service de pneumologie, CHU d'Amiens-Picardie, Amiens, France; Université de Picardie Jules-Verne, UR 4294 AGIR, Amiens, France.
Service de pneumologie, CHU d'Amiens-Picardie, Amiens, France; Université de Picardie Jules-Verne, UR 4294 AGIR, Amiens, France.
Rev Mal Respir. 2021 Jun;38(6):616-625. doi: 10.1016/j.rmr.2021.04.014. Epub 2021 Apr 30.
Since January 2020, when the first cases of SARS-CoV-2 infection were diagnosed in France, pulmonologists have been at the heart of the crisis and should be responsible for the management of acute COVID-19 (and any possible sequelae) BACKGROUND: Many drugs have been evaluated or are currently under evaluation as possible specific treatment for SARS-CoV-2. Nevertheless, as of April 15, 2021, the only recommended treatment in current practice is the "standard of care", i.e. the symptomatic management of infection with SARS-CoV-2. This review presents the state of knowledge on COVID-19 in the acute phase (virological, immunological, epidemiological and therapeutic data) available on 15th April, 2021.
A large number of clinical trials are currently ongoing. It is important to propose to patients the opportunity to participate in clinical trials and to structure the research in order to complete the studies.
Current management is based on oxygen therapy, thromboprophylaxis and in some cases corticosteroids. No antiviral therapy is currently recommended. These data are constantly evolving.
自2020年1月法国确诊首例新型冠状病毒肺炎（COVID-19）感染病例以来，肺科医生一直处于这场危机的核心，应负责急性COVID-19（以及任何可能的后遗症）的管理。背景：许多药物已被评估或正在评估中，作为SARS-CoV-2可能的特异性治疗方法。然而，截至2021年4月15日，目前实践中唯一推荐的治疗方法是“标准治疗”，即对SARS-CoV-2感染进行对症治疗。本综述介绍了截至2021年4月15日可获得的关于COVID-19急性期的知识状态（病毒学、免疫学、流行病学和治疗数据）。
目前正在进行大量临床试验。向患者提供参与临床试验的机会并组织研究以完成这些研究很重要。
目前的治疗基于氧疗、血栓预防，在某些情况下还包括使用皮质类固醇。目前不推荐使用抗病毒治疗。这些数据在不断演变。
